Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Chordoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Malignancies 1 Advanced Liver Cancers 1

Interventions

Specimen Handling 53 pembrolizumab 51 Carboplatin 51 Magnetic Resonance Spectroscopy 46 Pemetrexed 41 Cisplatin 36 Paclitaxel 25 durvalumab 24 osimertinib 22 Nivolumab 22 Gemcitabine 20 Radiosurgery 18 Radiotherapy 17 Docetaxel 17 atezolizumab 15 Immunoglobulin G 15 Biopsy 15 Disulfides 14 130-nm albumin-bound paclitaxel 13 Taxes 12 Radiation 12 Educational Status 12 Etoposide 11 Blood Specimen Collection 11 Early Intervention, Educational 10 Drug Therapy 10 Practice Guidelines as Topic 9 Platinum 9 Methods 9 Cetuximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Tiragolumab × 90 days × Clear all

NCT06713798 2026-03-23

INDIGO

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡